Phase
Startup
Transient Pharma
Investment: 2 million SEK
Transient Pharma develops innovative systemic anti-inflammatory treatments, focusing initially on gastrointestinal inflammatory disorders and curbing the excessive inflammation during acute infections.
Helene Hartman is the co-founder of Transient Pharma AB, with extensive experience in technology, product, and business development in multinational settings. She is also the founder and CEO of Xinnate AB, a biotech company advancing its primary drug candidate through clinical development. Helene has served on Boards of Directors in the financial and life science sectors.
